New Delhi, Oct. 22 -- Biocon Biologics Ltd is aiming to expand its insulin portfolio in the US market, as global innovators focus on more lucrative anti-obesity GLP-1 therapies.

Biocon Ltd's biosimilar arm, which holds a 15-17% share in the US insulin market, recently announced it will supply insulin glargine pens to US-based non-profit Civica, which will commercialize them at low cost in California.

The idea is to expand this model across all US states, Shreehas Tambe, the firm's chief executive and managing director, told Mint in an interview.

Under a multi-year exclusive distributorship agreement announced on 16 October, Biocon Biologics will manufacture and supply insulin glargine pens to Civica, which will commercialize them under...